




Amarin Corporation plc
Investor Relations Department
2 Pembroke House, Upper
Pembroke
Street 28-32
Dublin 2
Ireland

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: AMRN

Last Trade:	3.96
Trade Time:	3:56 PM ET Jan 19, 2018
Change:	-0.02  (-0.503%)
Day Range	3.93 - 4.02
52-Week Range	2.81 - 4.47
Volume	1,094,584

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jan 17, 2018

[Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China](#)

Jan 4, 2018

[Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook](#)

Dec 19, 2017

[Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018](#)

Dec 18, 2017

[Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco](#)

Nov 14, 2017

[Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 2, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)